Intragastric Balloon Market - Global Forecast 2025-2032

The intragastric balloon market is progressing as healthcare leaders seek non-surgical options to address weight management, balancing operational efficiency with proven outcomes. As demand rises globally, shifting policies and technological innovation are shaping strategic priorities for decision-makers across regions.

Market Snapshot: Intragastric Balloon Market Overview

The intragastric balloon market grew from USD 21.95 million in 2024 to USD 23.79 million in 2025 and is projected to reach USD 41.75 million by 2032, demonstrating a CAGR of 8.36%. This sustained growth is driven by senior executives and procurement leaders favoring scalable, minimally invasive therapies that target the rising prevalence of obesity and metabolic conditions. Increased adoption stems from the urgent need for interventions that offer improved patient outcomes, manageable resource allocation, and expanded treatment capacity across diverse healthcare systems. Industry leaders are leveraging these solutions to enhance competitive positioning while responding to evolving clinical expectations and payer criteria.

Scope & Segmentation: Intragastric Balloon Market Coverage

This comprehensive report delivers actionable segmentation supporting strategic operations and investment decisions across the following dimensions:

• Device Types: Includes both endoscopic solutions (featuring gas-filled and liquid-filled options) and non-endoscopic designs to support varying clinical needs and patient preferences.
• End User Settings: Addresses deployment in bariatric centers, clinics—encompassing outpatient and specialty facilities—and acute-care hospitals, highlighting operational diversity and adoption by multidisciplinary teams.
• Distribution Channels: Focuses on both hospital and retail pharmacy networks, crucial for therapy accessibility and patient follow-up, and for ensuring seamless engagement through established healthcare infrastructure.
• Applications: Covers use in preoperative weight optimization as well as primary, direct weight-loss interventions, supporting multiple patient pathways and expanding referral sources.
• Regional Coverage: Features comprehensive data on the Americas (including North and Latin America), Europe, the Middle East, Africa, and Asia-Pacific markets to inform regional investment and policy approaches.
• Featured Companies: Catalogs key players shaping global and regional competitive dynamics: Apollo Endosurgery, Inc.; Allurion Technologies, Inc.; Obalon Therapeutics, Inc.; ReShape Lifesciences, Inc.; Spatz Medical, Inc.; MedSil, UAB; Silimed, S.A.; ENDALIS GmbH; GI Dynamics, Inc.; and BARIATRX Ltd.

Key Takeaways for Senior Decision-Makers

• Intragastric balloon adoption is transitioning from support for surgical candidates to standalone weight-loss modalities, as device designs become less invasive and better tolerated by patients.
• Research and development emphasizes advanced biocompatible materials and integration of monitoring sensors, supporting long-term efficacy and facilitating remote patient management via digital health platforms.
• Collaborative agreements—including technology licensing, local assembly partnerships, and digital solution alliances—are advancing tailored care models and reducing time to market across regulatory environments.
• Policy evolution and payer engagement are enhancing reimbursement opportunities as the cost-efficiency and safety of minimally invasive therapies gain recognition among providers and insurers.
• Comprehensive aftercare services, such as tele-nutrition and personalized follow-up protocols, are being implemented to ensure improved patient satisfaction and sustained adherence to prescribed regimens.

Tariff Impact on Supply Chains and Procurement

Recent adjustments to U.S. tariffs have prompted manufacturers in the intragastric balloon market to reevaluate their supply chain strategies. Companies are actively nearshoring operations, renegotiating agreements with national suppliers, and refining logistics to control expenses and protect supply stability. Healthcare providers have adjusted procurement approaches, including adopting bundled service purchasing and risk-sharing contracts to manage changing cost structures without compromising patient care quality. Collaboration with customs experts supports compliance and effective management of duties in dynamic trade environments.

Methodology & Data Sources

This report employs a rigorous mixed-methods approach. Primary research incorporates interviews with clinicians, leading manufacturers, and payer representatives across crucial markets. Secondary validation is based on regulatory filings, multicenter trial records, and peer-reviewed articles. Systematic triangulation and repeated expert review underpin data quality and reliability.

Why This Report Matters

• Delivers robust market intelligence on technological advances and evolving regulatory and channel trends, enabling business leaders to anticipate and respond to change.
• Provides clear, actionable segmentation essential for targeted investments and long-term operational strategy in high-growth geographies and complex healthcare contexts.
• Guides decision-makers in mitigating supply chain risks, adapting to policy transitions, and innovating care models for improved stakeholder value.

Conclusion

The intragastric balloon market is positioned for continued development, fueled by integrated care models, patient-focused innovation, and effective multi-stakeholder collaboration. This report supports senior decision-makers as they navigate evolving priorities and deliver lasting therapeutic impact.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.